Literature DB >> 20720023

Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system.

Alex B Ryder1, Ying Huang, Haijing Li, Min Zheng, Xiaobo Wang, Charles W Stratton, Xiao Xu, Yi-Wei Tang.   

Abstract

We explored the use of a real-time cell analysis (RTCA) system for the assessment of Clostridium difficile toxins in human stool specimens by monitoring the dynamic responses of the HS27 cells to tcdB toxins. The C. difficile toxin caused cytotoxic effects on the cells, which resulted in a dose-dependent and time-dependent decrease in cell impedance. The RTCA assay possessed an analytical sensitivity of 0.2 ng/ml for C. difficile toxin B with no cross-reactions with other enterotoxins, nontoxigenic C. difficile, or other Clostridum species. Clinical validation was performed on 300 consecutively collected stool specimens from patients with suspected C. difficile infection (CDI). Each stool specimen was tested in parallel by a real-time PCR assay (PCR), a dual glutamate dehydrogenase and toxin A/B enzyme immunoassay (EIA), and the RTCA assay. In comparison to a reference standard in a combination of the three assays, the RTCA had a specificity of 99.6% and a sensitivity of 87.5% (28 of 32), which was higher than the EIA result (P = 0.005) but lower than the PCR result (P = 0.057). In addition, the RTCA assay allowed for quantification of toxin protein concentration in a given specimen. Among RTCA-positive specimens collected prior to treatment with metronidazole and/or vancomycin, a significant correlation between toxin protein concentrations and clinical CDI severities was observed (R(2) = 0.732, P = 0.0004). Toxin concentrations after treatment (0.89 ng/ml) were significantly lower than those prior to the treatment (15.68 ng/ml, Wilcoxon P = 0.01). The study demonstrates that the RTCA assay provides a functional tool for the potential assessment of C. difficile infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20720023      PMCID: PMC3020809          DOI: 10.1128/JCM.01104-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

Review 1.  Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review.

Authors:  Tim Planche; Adamma Aghaizu; Richard Holliman; Peter Riley; Jan Poloniecki; Aodhán Breathnach; Sanjeev Krishna
Journal:  Lancet Infect Dis       Date:  2008-11-01       Impact factor: 25.071

Review 2.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

3.  Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.

Authors:  Paul D Stamper; Romina Alcabasa; Deborah Aird; Wisal Babiker; Jennifer Wehrlin; Ijeoma Ikpeama; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

4.  Application of isothermal helicase-dependent amplification with a disposable detection device in a simple sensitive stool test for toxigenic Clostridium difficile.

Authors:  Wing Huen A Chow; Cindy McCloskey; Yanhong Tong; Lin Hu; Qimin You; Ciarán P Kelly; Huimin Kong; Yi-Wei Tang; Wen Tang
Journal:  J Mol Diagn       Date:  2008-07-31       Impact factor: 5.568

5.  Algorithm combining toxin immunoassay and stool culture for diagnosis of Clostridium difficile infection.

Authors:  Bo-Moon Shin; Eun Young Kuak; Eun Joo Lee; J Glenn Songer
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

6.  An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins.

Authors:  Xiangyun He; Jufang Wang; Jennifer Steele; Xingmin Sun; Weijia Nie; Saul Tzipori; Hanping Feng
Journal:  J Microbiol Methods       Date:  2009-04-23       Impact factor: 2.363

7.  Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea.

Authors:  Lance R Peterson; Rebecca U Manson; Suzanne M Paule; Donna M Hacek; Ari Robicsek; Richard B Thomson; Karen L Kaul
Journal:  Clin Infect Dis       Date:  2007-09-25       Impact factor: 9.079

Review 8.  Antimicrobial resistance in Clostridium difficile.

Authors:  Haihui Huang; Andrej Weintraub; Hong Fang; Carl Erik Nord
Journal:  Int J Antimicrob Agents       Date:  2009-10-13       Impact factor: 5.283

9.  Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections.

Authors:  Haihui Huang; Andrej Weintraub; Hong Fang; Carl Erik Nord
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

10.  Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile?

Authors:  Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2008-02-06       Impact factor: 5.948

View more
  43 in total

Review 1.  Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection.

Authors:  Nira R Pollock
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

2.  Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.

Authors:  Bin Huang; Dazhi Jin; Jing Zhang; Janet Y Sun; Xiaobo Wang; Jeffrey Stiles; Xiao Xu; Mini Kamboj; N Esther Babady; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

3.  Reply to Planche et al.

Authors:  Krishna Rao; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2015-06-19       Impact factor: 9.079

4.  Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality.

Authors:  Krishna Rao; Dejan Micic; Mukil Natarajan; Spencer Winters; Mark J Kiel; Seth T Walk; Kavitha Santhosh; Jill A Mogle; Andrzej T Galecki; William LeBar; Peter D R Higgins; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2015-03-31       Impact factor: 9.079

5.  Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?

Authors:  Ferric C Fang; Christopher R Polage; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

6.  Clostridium difficile testing: have we got it right?

Authors:  Wei-Yuen Su; Joanne Mercer; Sebastiaan J Van Hal; Michael Maley
Journal:  J Clin Microbiol       Date:  2012-10-24       Impact factor: 5.948

7.  Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China.

Authors:  Dazhi Jin; Yun Luo; Chen Huang; Jian Cai; Julian Ye; Yi Zheng; Liqian Wang; Peng Zhao; Anbing Liu; Weijia Fang; Xianjun Wang; Shichang Xia; Jianmin Jiang; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2016-12-14       Impact factor: 5.948

8.  Quantitative detection of Vibrio cholera toxin by real-time and dynamic cytotoxicity monitoring.

Authors:  Dazhi Jin; Yun Luo; Min Zheng; Haijing Li; Jing Zhang; Melinda Stampfl; Xiao Xu; Gangqiang Ding; Yanjun Zhang; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2013-09-18       Impact factor: 5.948

9.  Quantification of the adenylate cyclase toxin of Bordetella pertussis in vitro and during respiratory infection.

Authors:  Joshua C Eby; Mary C Gray; Jason M Warfel; Christopher D Paddock; Tara F Jones; Shandra R Day; James Bowden; Melinda D Poulter; Gina M Donato; Tod J Merkel; Erik L Hewlett
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

10.  Outcomes in patients tested for Clostridium difficile toxins.

Authors:  Christopher R Polage; David L Chin; Jhansi L Leslie; Jevon Tang; Stuart H Cohen; Jay V Solnick
Journal:  Diagn Microbiol Infect Dis       Date:  2012-09-23       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.